{
    "clinical_study": {
        "@rank": "50300", 
        "arm_group": [
            {
                "arm_group_label": "Lung adenocarcinoma", 
                "description": "This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.\nat the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
            }, 
            {
                "arm_group_label": "Breast adenocarcinoma", 
                "description": "This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.\nat the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
            }, 
            {
                "arm_group_label": "Pancreatic ductal adenocarcinoma", 
                "description": "This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.\nat the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63."
            }
        ], 
        "brief_summary": {
            "textblock": "The p63 gene is a recently discovered member of the p53 family located at chromosome\n      3q27Many studies have reported that overexpression of p63 can mimic p53 activities by\n      binding DNA, activating transcription, and inducing apoptosis.\n\n      Various studies proved p63 as a marker of basal cells in normal salivary glands, breast,\n      prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies.\n      Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast\n      carcinoma, and no study has described the correlation of p63 with pancreatic ductal\n      adenocarcinoma.\n\n      In the current study, we aim to evaluate the prognostic value of the expression of p63 in\n      the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We\n      will achieve this aim by collecting clinical data retrospectively from the patients' medical\n      records as well as assessing the histological sections and performing immunohistochemical\n      staining for p63."
        }, 
        "brief_title": "Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Adenocarcinoma", 
            "Breast Adenocarcinoma", 
            "Pancreatic Ductal Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Lung Neoplasms", 
                "Breast Neoplasms", 
                "Carcinoma, Ductal, Breast"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who were treated at our institution for lung adenocarcinoma,   breast\n             adenocarcinoma, or pancreatic ductal adenocarcinoma.\n\n          -  Available histopathological diagnosis of the malignancy.\n\n        Exclusion Criteria:\n\n          -  Patients with inoperable tumors.\n\n          -  Patients with second primary tumor.\n\n          -  Patients with pathological blocks not enough for future slicing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "300 patients, 100 for each group."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01942629", 
            "org_study_id": "0298-13ctil"
        }, 
        "intervention": {
            "arm_group_label": [
                "Lung adenocarcinoma", 
                "Breast adenocarcinoma", 
                "Pancreatic ductal adenocarcinoma"
            ], 
            "intervention_name": "their will be no intervention in any of the groups, the study is retrospective", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Pancrelipase"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "prognostic markers,Pancreatic ductal adenocarcinoma", 
        "lastchanged_date": "September 10, 2013", 
        "number_of_groups": "3", 
        "official_title": "Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ethics Commission", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "if the patient is alive or dead 5 years following the treatment", 
            "measure": "5 year overall survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01942629"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rambam Health Care Campus", 
            "investigator_full_name": "SHOROOK NA'ARA MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "the recurrence of the disease within 5 years from the treatment", 
            "measure": "recurrence free survival", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "Rambam Health Care Campus", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rambam Health Care Campus", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}